Recent Quotes (30 days)

You have no recent quotes
chg | %

Kite Pharma Inc  

(Public, NASDAQ:KITE)   Watch this stock  
Find more results for KITE
-0.72 (-1.51%)
After Hours: 46.96 0.00 (0.00%)
Jul 12, 4:07PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 46.89 - 48.38
52 week 38.41 - 89.84
Open 48.04
Vol / Avg. 1.12M/1.02M
Mkt cap 2.27B
P/E     -
Div/yield     -
EPS -2.85
Shares 49.13M
Beta     -
Inst. own 85%
Aug 8, 2016
Q2 2016 Kite Pharma Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 7, 2016
Kite Pharma Inc at Goldman Sachs Global Healthcare Conference
Jun 7, 2016
Kite Pharma Inc at Jefferies Healthcare Conference
Jun 1, 2016
Kite Pharma Inc Annual Shareholders Meeting
May 9, 2016
Q1 2016 Kite Pharma Inc Earnings Call
May 9, 2016
Q1 2016 Kite Pharma Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin -856.56% -589.02%
Operating margin -892.94% -598.67%
EBITD margin - -588.84%
Return on average assets -25.40% -18.85%
Return on average equity -29.23% -20.78%
Employees 185 -
CDP Score - -


2225 Colorado Ave
SANTA MONICA, CA 90404-3505
United States - Map
+1-310-8249999 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company offers engineered autologous cell therapy (eACT), which is an approach to the treatment of cancer. It is conducting over four pivotal studies of its lead product candidate, KTE-C19, a CAR-based therapy. It is conducting a Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with refractory diffuse large B cell lymphoma (DLBCL), including primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is also conducting a Phase II clinical trial (ZUMA-2) of KTE-C19 in patients with relapsed/refractory mantle cell lymphoma (MCL), a Phase I-II clinical trial (ZUMA-3) of KTE-C19 in adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL), and a Phase I-II clinical trial (ZUMA-4) of KTE-C19 in pediatric patients with relapsed/refractory ALL.

Officers and directors

Arie S. Belldegrun Executive Chairman of the Board, President, Chief Executive Officer, Founder
Age: 66
Bio & Compensation  - Reuters
Paul L. Jenkinson Chief Financial Officer
Age: 56
Bio & Compensation  - Reuters
Cynthia M. Butitta Chief Operating Officer
Age: 61
Bio & Compensation  - Reuters
David D Chang M.D., Ph.D. Executive Vice President - Research and Development, Chief Medical Officer
Age: 55
Bio & Compensation  - Reuters
Helen S. Kim Executive Vice President - Business Development
Age: 52
Bio & Compensation  - Reuters
Timothy L. Moore Executive Vice President - Technical Operations
Bio & Compensation  - Reuters
Margo R. Roberts Ph.D. Chief Scientific Officer
Age: 59
Bio & Compensation  - Reuters
Marc D. Better Ph.D. Vice President - Product Sciences
Age: 59
Bio & Compensation  - Reuters
Rizwana F. Sproule Vice President - Regulatory Affairs
Age: 53
Bio & Compensation  - Reuters
Jeffrey Wiezorek M.D. Vice President - Clinical Development
Age: 43
Bio & Compensation  - Reuters